Serina Therapeutics, Inc. (SER)
2.105
-0.14
(-6.44%)
USD |
NYAM |
Sep 21, 16:00
2.105
0.00 (0.00%)
After-Hours: 20:00
Serina Therapeutics Enterprise Value : 37.34M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 37.34M |
| September 17, 2026 | 36.57M |
| September 16, 2026 | 35.05M |
| September 15, 2026 | 39.88M |
| September 14, 2026 | 42.42M |
| September 11, 2026 | 36.57M |
| September 10, 2026 | 43.68M |
| September 09, 2026 | 45.46M |
| September 08, 2026 | 43.68M |
| September 04, 2026 | 49.53M |
| September 03, 2026 | 48.51M |
| September 02, 2026 | 46.73M |
| September 01, 2026 | 43.68M |
| August 31, 2026 | 41.65M |
| August 28, 2026 | 42.67M |
| August 27, 2026 | 44.19M |
| August 26, 2026 | 46.99M |
| August 25, 2026 | 48.76M |
| August 24, 2026 | 46.99M |
| August 21, 2026 | 53.08M |
| August 20, 2026 | 47.50M |
| August 19, 2026 | 49.27M |
| August 18, 2026 | 46.73M |
| August 17, 2026 | 52.58M |
| August 14, 2026 | 51.30M |
| Date | Value |
|---|---|
| August 13, 2026 | 52.58M |
| August 12, 2026 | 51.81M |
| August 11, 2026 | 50.80M |
| August 10, 2026 | 48.00M |
| August 07, 2026 | 41.14M |
| August 06, 2026 | 39.88M |
| August 05, 2026 | 36.83M |
| August 04, 2026 | 34.54M |
| August 03, 2026 | 32.51M |
| July 31, 2026 | 30.98M |
| July 30, 2026 | 32.00M |
| July 29, 2026 | 32.76M |
| July 28, 2026 | 32.76M |
| July 27, 2026 | 33.52M |
| July 24, 2026 | 32.76M |
| July 23, 2026 | 33.27M |
| July 22, 2026 | 35.30M |
| July 21, 2026 | 33.27M |
| July 20, 2026 | 35.56M |
| July 17, 2026 | 34.29M |
| July 16, 2026 | 30.48M |
| July 15, 2026 | 29.72M |
| July 14, 2026 | 33.27M |
| July 13, 2026 | 32.26M |
| July 10, 2026 | 34.54M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
| Sangamo Therapeutics, Inc. | 51.77M |
| Sarepta Therapeutics, Inc. | 2.381B |
| Anixa Biosciences, Inc. | 80.84M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.356M |
| Total Expenses (Quarterly) | 6.356M |
| EPS Diluted (Quarterly) | -0.5451 |
| Earnings Yield | -89.20% |
| Normalized Earnings Yield | -106.33 |